Literature DB >> 7692666

Human herpesvirus-6 glycoprotein H and L homologs are components of the gp100 complex and the gH external domain is the target for neutralizing monoclonal antibodies.

D X Liu1, U A Gompels, L Foa-Tomasi, G Campadelli-Fiume.   

Abstract

Previous studies have shown that monoclonal antibody (MAb) 2E4 neutralizes infectivity of human herpesvirus-6 (HHV-6) and also inhibits virus-induced T-lymphocyte syncytia formation. Here we characterize two additional MAbs, 1D3 and 5E7, which have similar properties, and identify the glycoprotein targets. The MAbs could immunoprecipitate and immunofluorescence glycoprotein from both A and B variant strain groups of HHV-6. In reactions with infected cells the MAbs immunoprecipitated a complex of glycoproteins, the "gp100" complex, composed of a major glycoprotein species of 100,000 M(r) and minor components of 80,000 M(r) and 32,000 M(r). We show that the 100,000 M(r) product and most likely the 80,000 M(r) correspond to the HHV-6 homologue of herpes simplex virus-1 (HSV-1) glycoprotein H (gH) while the 32,000 M(r) species corresponds to the glycoprotein L (gL) equivalent. All three MAbs could specifically immunoprecipitate either gH expressed on its own in fibroblasts or a complex of gH and gL co-expressed, but could not immunoprecipitate gL expressed on its own. Consistent with these results, the MAbs could recognize gH in an immunofluorescence assay but not gL. Therefore although the MAbs recognized the complex of glycoproteins, they appeared specific for gH. The HHV-6 glycoproteins were produced in a transient expression system induced by T7-vaccinia virus. Immunoprecipitations were carried out in comparisons with an "epitope-tagged" gH, a recombinant glycoprotein designed to contain at the N-terminus the linear epitope for MAb LP14, raised originally against HSV-1 glycoprotein gD. The epitope-tagged gH was also used as a positive control in determining the domain of HHV-6 gH to which MAbs 2E4, 1D3 and 5E7 were directed. Two gH deletions were constructed, one deleting sequences which may serve as a transmembrane and cytoplasmic anchor domains, the second deleting also part of the external domain. MAb LP14 could immunoprecipitate both HHV-6 gH deletions but the gp100 MAbs recognized only the full-length product or the intact external domain minus the transmembrane and cytoplasmic domains. This indicated the epitopes for these MAbs are contained in the external domain of gH, consistent with the MAbs action in neutralization of virion infectivity and inhibition of virus to cell spread by T-lymphocyte fusion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692666     DOI: 10.1006/viro.1993.1562

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  24 in total

Review 1.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Complementation of the function of glycoprotein H of human herpesvirus 6 variant A by glycoprotein H of variant B in the virus life cycle.

Authors:  Hiroko Oyaizu; Huamin Tang; Megumi Ota; Nobuyuki Takenaka; Keiichi Ozono; Koichi Yamanishi; Yasuko Mori
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

3.  Site-directed and linker insertion mutagenesis of herpes simplex virus type 1 glycoprotein H.

Authors:  M Galdiero; A Whiteley; B Bruun; S Bell; T Minson; H Browne
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect.

Authors:  X Wang; L M Hutt-Fletcher
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

5.  Epitope mapping of herpes simplex virus type 2 gH/gL defines distinct antigenic sites, including some associated with biological function.

Authors:  Tina M Cairns; Marie S Shaner; Yi Zuo; Manuel Ponce-de-Leon; Isabelle Baribaud; Roselyn J Eisenberg; Gary H Cohen; J Charles Whitbeck
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

6.  Mutations of Epstein-Barr virus gH that are differentially able to support fusion with B cells or epithelial cells.

Authors:  Liguo Wu; Corina M Borza; Lindsey M Hutt-Fletcher
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Intracellular processing of human herpesvirus 6 glycoproteins Q1 and Q2 into tetrameric complexes expressed on the viral envelope.

Authors:  Pilailuk Akkapaiboon; Yasuko Mori; Tomohiko Sadaoka; Sayoko Yonemoto; Koichi Yamanishi
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells.

Authors:  X Wang; W J Kenyon; Q Li; J Müllberg; L M Hutt-Fletcher
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Discovery of a second form of tripartite complex containing gH-gL of human herpesvirus 6 and observations on CD46.

Authors:  Yasuko Mori; Pilailuk Akkapaiboon; Sayoko Yonemoto; Masato Koike; Masaya Takemoto; Tomohiko Sadaoka; Yumi Sasamoto; Shozo Konishi; Yasuo Uchiyama; Koichi Yamanishi
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  The human herpesvirus 6 U100 gene product is the third component of the gH-gL glycoprotein complex on the viral envelope.

Authors:  Yasuko Mori; Pilailuk Akkapaiboon; Xuwei Yang; Koichi Yamanishi
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.